rance’s anti-trust regulator has fined a Johnson & Johnson subsidiary nearly $30 million for running a “smear campaign” to thwart generic competition to its Durogesic painkiller, which is sold as a skin patch.

The fine, announced Wednesday, singles out two actions by the Janssen-Cilag unit of J&J.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Basically J&J is accused of competing by raising issues with the generic form of Durogesic with healthcare professionals. Is what they were saying true? Or in violation of a regulation? These points aren’t mentioned. If so, then there’s a valid case. But if J&J was making truthful points, I fail to see the basis of this complaint.
    Competing and making valid points (assuming they are such) is competition. Because it’s a brand competing with a generic, it’s somehow wrong?
    Seems to me the French complaint is simply about the money.
    I’m not saying all the other anti-competitive examples noted here are OK, but that’s not what I see happening in this situation.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.